Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Advancements in health care monitoring demand a rapid, accurate and reliable early diagnosis of "Heart Attack" (acute myocardial infarction) with an objective to develop a cost-effective, rapid and label-free point of care diagnostic test kit for the detection of cardiac troponin I (cTnI) on paper-based multi-frequency impedimetric transducers.
|
31844990 |
2019 |
Myocardial Infarction
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A novel high-sensitivity cardiac troponin I assay can safely identify patients at low risk of myocardial infarction or cardiac death.
|
30442743 |
2019 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
This work demonstrates the application of the LRSPP biosensors for the detection of human cardiac troponin I (cTnI) protein. cTnI is a biological marker for acute myocardial infarction (AMI), often referred to as a heart attack, which can be diagnosed by elevated levels of cTnI in patient blood.
|
30717341 |
2019 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Six-hour cardiac troponin I (cTnI) was measured with a primary end point of PMI defined as rise ≫×5 upper limit of normal (280 ng/L).
|
31277053 |
2019 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the impact of implementing a high-sensitivity cardiac troponin I assay with sex-specific diagnostic thresholds for myocardial infarction in women and men with suspected acute coronary syndrome.
|
31623760 |
2019 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical Use of a New High-Sensitivity Cardiac Troponin I Assay in Patients with Suspected Myocardial Infarction.
|
31570633 |
2019 |
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exogenous NADPH (8-16 mg/kg) significantly decreased myocardial infarct size and reduced serum levels of lactate dehydrogenase (LDH) and cardiac troponin I (cTn-I).
|
31776448 |
2019 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
A nanozyme-linked immunosorbent assay is described for cardiac troponin I which is a biomarker for myocardial infarction.
|
30989395 |
2019 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the basis of this fascinating sensing platform, a robust label-free ECL immunosensor was constructed for ultrasensitive detection of cTnI, the main marker of myocardial infarction, with good stability and a detection limit as low as 0.58 fg mL<sup>-1</sup> (S/N = 3).
|
30680992 |
2019 |
Myocardial Infarction
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to evaluate the diagnostic ability of absolute and relative conventional cardiac troponin I (cTnI) and high-sensitivity cardiac troponin T (hs-cTnT) in the distinction between type 1 and type 2 MI in patients presenting at the emergency department with non-ST-segment elevation acute chest pain within the first 12 h.
|
29303766 |
2018 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rapidity and high sensitivity are the critical factors for the diagnoses of heart attacks and cardiac troponin I (cTnI) is used as a gold standard marker for its diagnosis.
|
29935487 |
2018 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the basis of the simple sandwich immunoreaction approach, cardiac troponin-I antigen (cTnI), a kind of biomarker related with myocardial infarction, was chosen as a detection model using an IRMOF-3-enriched CdTe labeled antibody as the signal probe.
|
29457712 |
2018 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cardioprotective potential of CuNP (1mg/kg/day, po, 4 weeks) and exercise (swimming, 90min, 5days/4 weeks) either alone or in combination was estimated by measuring the surge in serum nitrite/nitrate concentration and reduction in creatine kinase MB (CKMB), lactate dehydrogenase (LDH), cardiac troponin I (cTnI), lipid profile, oxidative stress, structural abnormalities against isproterenol (ISO)-induced MI.
|
29957339 |
2018 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prospective studies measuring high-sensitivity cardiac troponin I concentrations in patients with suspected acute coronary syndrome in which the diagnosis was adjudicated according to the universal definition of myocardial infarction.
|
29127948 |
2017 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, enhanced NMDAR activity under I/R conditions produced significant increases in [Ca]i levels (∼1.2% increase), significant losses in left ventricular function (∼5.4% decrease), significant multi-fold increases in creatine kinase, creatine kinase isoenzyme MB, lactate dehydrogenase, cardiac troponin I, and cardiac troponin T, significant increases in generalized myocardial necrosis (∼36% increase) and apoptosis (∼150% increase), and significant multi-fold increases in PKC-δ, PKC-ε, Akt, and extracellular signal-regulated kinase phosphorylation (all P < 0.05).
|
28777252 |
2017 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ultrasensitive cardiac troponin I antibody based nanohybrid sensor for rapid detection of human heart attack.
|
27865959 |
2017 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human cardiac troponin-I (cTnI) is one of the most sensitive and specific indicators, used in the diagnosis of myocardial infarction.
|
27070210 |
2017 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Type 1 and 2 Myocardial Infarction and Myocardial Injury: Clinical Transition to High-Sensitivity Cardiac Troponin I.
|
28739197 |
2017 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Objective</b> To evaluate how selection of patients for high sensitivity cardiac troponin testing affects the diagnosis of myocardial infarction across different healthcare settings.<b>Design</b> Prospective study of three independent consecutive patient populations presenting to emergency departments.<b>Setting</b> Secondary and tertiary care hospitals in the United Kingdom and United States.<b>Participants</b> High sensitivity cardiac troponin I concentrations were measured in 8500 consecutive patients presenting to emergency departments: unselected patients in the UK (n=1054) and two selected populations of patients in whom troponin testing was requested by the attending clinician in the UK (n=5815) and the US (n=1631).
|
29114078 |
2017 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Copeptin is a marker of endogenous stress including early myocardial infarction(MI) and has value in early rule out of MI when used with cardiac troponin I(cTnI).
|
27847253 |
2017 |
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The nRIC group repeatedly underwent 5 min of ischemia and 5 min of reperfusion in the left hind limb for three cycles every other day until weeks 4, 6, and 8 after MI. nRIC improved cardiac hemodynamic function and mitochondrial respiratory function through increasing myocardial levels of mitochondrial respiratory chain complexes I, II, III, IV, and adenosine triphosphate (ATP) and decreasing the activity of nitric oxide synthase (NOS). nRIC could inhibit cardiomyocytes apoptosis and reduce myocardium injury through raising the expression of Bcl-2 and reduced the content of creatine kinase-MB, cardiac troponin I and Bax.
|
28479248 |
2017 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among the 249 adjudicated MIs using the contemporary cTnI, only 69 (28%) were ICD-coded MIs.
|
27811209 |
2017 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intracoronary Bb increased immediately after AXCL, and the levels were directly correlated with peripheral blood levels of cardiac troponin I, an established biomarker of myocardial necrosis (Spearman coefficient = 0.465, P < 0.01).
|
28662037 |
2017 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Algorithms incorporating cardiac troponin and glucose for early rule-in/rule-out were the most cost effective and clinically safest methods (i.e., ≤1 MI missed) for early decision making, with hs-cTnI and glucose yielding lower costs compared to cTnI and glucose, despite the higher price for the hs-cTnI test.
|
27811206 |
2017 |
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, immunohistochemistry revealed that HSV-tk-labelled BMSCs-derived cells were positive for cardiac troponin I. Multimodal imaging systems combining an α-MHC-HSV1-tk/<sup>18</sup>F-FHBG reporter gene and <sup>18</sup>F-FDG metabolism imaging could be used to track differentiation of transplanted BMSCs and recovery of cardiac function in MI.
|
28740146 |
2017 |